BR112020021631A8 - Composto oxo-substituído - Google Patents

Composto oxo-substituído

Info

Publication number
BR112020021631A8
BR112020021631A8 BR112020021631A BR112020021631A BR112020021631A8 BR 112020021631 A8 BR112020021631 A8 BR 112020021631A8 BR 112020021631 A BR112020021631 A BR 112020021631A BR 112020021631 A BR112020021631 A BR 112020021631A BR 112020021631 A8 BR112020021631 A8 BR 112020021631A8
Authority
BR
Brazil
Prior art keywords
compound
beta
oxo
preventive
inhibitory effect
Prior art date
Application number
BR112020021631A
Other languages
English (en)
Other versions
BR112020021631A2 (pt
Inventor
Kanai Toshio
Koike Sachiko
Fukaya Takayuki
Uesugi Shunichiro
Mizushima Shingo
Suda Hitoshi
Mizukami Yuki
Ikuma Yohei
Sunazuka Toshiaki
Noguchi Yoshihiko
Original Assignee
The Kitasato Inst
Sumitomo Dainippon Pharma Co Ltd
Sumitomo Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=68295570&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112020021631(A8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by The Kitasato Inst, Sumitomo Dainippon Pharma Co Ltd, Sumitomo Pharma Co Ltd filed Critical The Kitasato Inst
Publication of BR112020021631A2 publication Critical patent/BR112020021631A2/pt
Publication of BR112020021631A8 publication Critical patent/BR112020021631A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/027—Organoboranes and organoborohydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cephalosporin Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

COMPOSTO OXO-SUBSTITUÍDO. A presente invenção refere-se a um novo composto que tem um excelente efeito inibidor da beta-lactamase. Mais especificamente, é fornecido um composto representado pela fórmula (1a), (1b) ou (11) tendo um excelente efeito inibitório da beta-lactamase ou um sal farmaceuticamente aceitável do mesmo. Usando este composto em combinação com um fármaco beta-lactâmico ou sozinho, é fornecido um agente preventivo ou terapêutico útil para infecções bacterianas. São também fornecidos agentes preventivos ou terapêuticos úteis para o tratamento de várias doenças com o uso combinado do composto precedentemente referido e fármacos beta-lactâmicos.
BR112020021631A 2018-04-27 2019-04-26 Composto oxo-substituído BR112020021631A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2018087761 2018-04-27
JP2018-087761 2018-04-27
PCT/JP2019/018011 WO2019208797A1 (ja) 2018-04-27 2019-04-26 オキソ置換化合物

Publications (2)

Publication Number Publication Date
BR112020021631A2 BR112020021631A2 (pt) 2021-01-26
BR112020021631A8 true BR112020021631A8 (pt) 2023-02-28

Family

ID=68295570

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112020021631A BR112020021631A8 (pt) 2018-04-27 2019-04-26 Composto oxo-substituído

Country Status (14)

Country Link
US (3) US11702431B2 (pt)
EP (1) EP3786168A4 (pt)
JP (2) JP7360132B2 (pt)
KR (1) KR20210005910A (pt)
CN (1) CN112135830A (pt)
AU (1) AU2019259818B2 (pt)
BR (1) BR112020021631A8 (pt)
CA (1) CA3098433A1 (pt)
EA (1) EA202092579A1 (pt)
MX (1) MX2020011367A (pt)
PH (1) PH12020551772A1 (pt)
SG (1) SG11202010661SA (pt)
TW (1) TWI829686B (pt)
WO (1) WO2019208797A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202038941A (zh) * 2018-12-28 2020-11-01 日商大日本住友製藥股份有限公司 烷基取代化合物
KR20220088736A (ko) * 2019-10-25 2022-06-28 스미토모 파마 가부시키가이샤 신규 치환 축환형 화합물

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2893943C (en) 2012-12-07 2021-03-02 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
US9642869B2 (en) 2013-01-04 2017-05-09 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
EP2941247A4 (en) 2013-01-04 2017-02-08 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
CN105101970B (zh) 2013-01-10 2018-11-20 维纳拓尔斯制药公司 β-内酰胺酶抑制剂
EP2970340B1 (en) 2013-03-14 2020-02-12 Venatorx Pharmaceuticals, Inc. Beta-lactamase inhibitors
CN106459096B (zh) * 2014-05-19 2019-03-08 莱姆派克斯制药公司 硼酸衍生物及其治疗用途
RU2686740C2 (ru) 2014-06-11 2019-04-30 Венаторкс Фармасьютикалс, Инк. Ингибиторы бета-лактамазы
EA201692301A1 (ru) 2014-07-01 2017-06-30 Ремпекс Фармасьютикалз, Инк. Производные бороновой кислоты и их терапевтическое применение
US20180051041A1 (en) 2015-03-17 2018-02-22 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US10399996B2 (en) * 2015-09-11 2019-09-03 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors

Also Published As

Publication number Publication date
JPWO2019208797A1 (ja) 2021-05-27
CA3098433A1 (en) 2019-10-31
MX2020011367A (es) 2021-02-09
US20210147448A1 (en) 2021-05-20
BR112020021631A2 (pt) 2021-01-26
SG11202010661SA (en) 2020-11-27
WO2019208797A1 (ja) 2019-10-31
US11066425B1 (en) 2021-07-20
PH12020551772A1 (en) 2021-07-12
JP7360132B2 (ja) 2023-10-12
AU2019259818B2 (en) 2023-06-01
EP3786168A1 (en) 2021-03-03
AU2019259818A1 (en) 2020-11-26
TWI829686B (zh) 2024-01-21
US11702431B2 (en) 2023-07-18
EP3786168A4 (en) 2022-03-23
JP2023168413A (ja) 2023-11-24
EA202092579A1 (ru) 2021-04-01
TW201945006A (zh) 2019-12-01
KR20210005910A (ko) 2021-01-15
US20230287009A1 (en) 2023-09-14
CN112135830A (zh) 2020-12-25

Similar Documents

Publication Publication Date Title
BR112021009595A2 (pt) Terapia de combinação incluindo um inibidor de krasg12c e um ou mais agentes farmaceuticamente ativos adicionais para o tratamento de cânceres
BR112015020302A2 (pt) derivado de pirazol
UY38186A (es) Sal sódica de n-((1,2,3,5,6,7-hexahidro-s-indacen-4-il)carbamoil)-1-isopropil-1h-pirazol-3-sulfonamida
BR112013032770A2 (pt) composições farmacêuticas compreendendo antibiótico beta-lactama, sulbactama e inibidor de beta-lactamase
BR112015029512A2 (pt) derivados de pirazolopirrolidina e seu uso no tratamento de doenças
PH12021551256A1 (en) Pantetheine derivatives and uses thereof
BRPI0616574A2 (pt) derivado de sulfonamida tendo atividade antagonìstica de receptor de pgd2
BR0306214A (pt) Composto de 4-oxoquinolina e uso deste como inibidor de integrase de hiv
BR112015018738A8 (pt) compostos de tetra-hidropirrolotiazina, seus usos, e composição farmacêutica
BR0113389A (pt) Compostos que inibem a atividade do fator xa
BR112020021631A8 (pt) Composto oxo-substituído
BR112021023927A2 (pt) Composto, e, composição farmacêutica
BR112018073553A2 (pt) medicamento e composição farmacêutica para a prevenção ou tratamento de fibromialgia ou sintomas funcionais associados com fibromialgia, método para prevenir ou tratar fibromialgia ou sintomas funcionais associados com fibromialgia em um indivíduo, e, uso de um composto carbamato.
BR112021018815A2 (pt) Gepotidacina para uso no tratamento de infecções bacterianas do trato urinário
BR112022010323A2 (pt) Composto, composto ou sal, medicamento, métodos para ativar um receptor tipo 2 de orexina e para prevenir ou tratar narcolepsia, e, uso do composto ou sal
BR112019024549A2 (pt) compostos derivados de glicopeptídeo e usos dos mesmos
BR112017015744A2 (pt) composto apresentando uma estrutura de fórmula (i), um sal farmaceuticamente aceitável do mesmo ou um isômero ótico do mesmo, composição farmacêutica e uso do composto de fórmula (i) para o tratamento e prevenção de mycobacterium tuberculosis ou outras infecções microbianas
BR112023000770A2 (pt) Inibidor de egfr
MX2022004912A (es) Novedoso compuesto de anillo condensado sustituido.
BR112019008698A2 (pt) método para tratar câncer num sujeito que precisa do mesmo e composição farmacêutica
BR112018073556A2 (pt) medicamento e composição farmacêutica para a prevenção ou o tratamento da neuralgia trigeminal, método para prevenir ou tratar neuralgia trigeminal em um indivíduo, e, uso de um composto de carbamato .
JOP20190278A1 (ar) مركبات 5، 6-ثنائية الحلقة مندمجة وتركيبات لعلاج الأمراض الطفيلية
BRPI0612534B8 (pt) uso de um composto derivado de quinolina, o referido composto, sua combinação, composição farmacêutica, uso da referida combinação, e produto
BR112023019657A2 (pt) Antagonista de abhd6
BR112022001809A2 (pt) Agente terapêutico e método para tratar câncer resistente ao anticorpo anti-ccr4, composto, e, uso de um composto

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B25D Requested change of name of applicant approved

Owner name: THE KITASATO INSTITUTE (JP) ; SUMITOMO PHARMA CO., LTD. (JP)

B25G Requested change of headquarter approved

Owner name: THE KITASATO INSTITUTE (JP) ; SUMITOMO PHARMA CO., LTD. (JP)

B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B09Y Publication of grant cancelled [chapter 9.1.2 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 9.1 NA RPI NO 2743 DE 01/08/2023 POR TER SIDO INDEVIDA.

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]